Prostate Cancer Foundation VL

Integrating Social Media as an Effective Teaching Tool for Patients - Stacy Loeb

Details
Stacy Loeb discusses with Alicia Morgans her successful implementation of a Twitter-based prostate cancer journal club for patients that was implemented in 2017, under #prostatejc. They also discuss the necessity to vet the quality of information available to consumers. Stacy refers to a content analysis of YouTube videos related to prostate cancer, published in 2017 in the American Journal of Men...

25 Years of Impact: The Prostate Cancer Foundation - Howard Soule

Details
Howard Soule, Executive Vice President & Chief Science Officer of the Prostate Cancer Foundation highlights PCFs 25th-year milestone in shaping the direction of prostate cancer research in this conversation with Alicia Morgans. Howard shares how the foundation was started, how it is impacting prostate cancer research and the future directions of the foundations impactful work. Howard shares his pe...

Targeting Glutamine Metabolism Pathways for the Treatment of Prostate Cancer - Richard Lee

Details
Richard Lee, a 2017 PCF Challenge Award recipient, discusses his research on the metabolics of prostate cancer. The upcoming Phase 1 research in men with CRPC is centered around inhibiting the glutaminase pathway in combination with a PARP inhibitor. The rationale for targeting the glutaminase pathway stems from the fact that cancer cells deplete glucose as a carbon source, a necessary element for...

Neoadjuvant Therapy Prior to Prostatectomy - Mary-Ellen Taplin

Details
In this conversation, Mary-Ellen Taplin reviews her work from the past nine years in the area of neoadjuvanct therapies prior to prostatectomy. Mary-Ellen discusses how research on combining systematic therapy with prostatectomy when next generation androgen-AR axis inhibitors were developed have now lead to the launch of a large, international phase 3 trial. Biographies: Mary-Ellen Taplin, MD Cha...

Life-Prolonging Treatments for Advanced Prostate Cancer - Maha Hussain

Details
Maha Hussain joins Alicia Morgans and reflects on the journey she has traveled from 1983 when prostate cancer was viewed as a disease exclusive to older men, where there were no real biomarkers and a lack of understanding for the spectrum of the disease. Maha delivers one of the pivotal talks at the PCF 25th Annual retreat and here we gain her perspective on the evolving landscape of life-prolongi...

Disparities in Prostate Cancer Clinical Trial Participation - Hala Borno

Details
Hala Borno and Charles Ryan discuss the ongoing and increasing problems in the enrollment of clinical trials in oncology. Hala describes her goals in this area and her passion for uncovering differences that lead to inequities. Hala is currently developing a patient facing tool called Trial Library, that is a clinical trial online matching website developed based on patient-prompted conversations...

Engagement in Long-Term Physical Activity and Lowering the Risk of Advanced Prostate Cancer - Lorelei Mucci

Details
Lorelei Mucci and Alicia Morgans discuss the findings of a large epidemiologic study examining physical activity and its influence on a wide range of biological processes including anti-inflammatory and insulin pathways, may be linked to a lower risk of prostate cancer. In addition to being one of the largest of its kind, the study stands out in that researchers were able to examine medical record...

Prostate Cancer Disparities in the VA Health System - Megan McNamara

Details
Dan George and Megan McNamara discuss the details of a project focused on prostate cancer disparities in the VA health system, leading to her 2018 PCF Young Investigator Award. This work builds upon the Abi Race trial and includes the PANTHER cohort focused on genomic data specific to the African American population. Part two of the project is an extension of the Moonshot Initiative where the VA h...

PROPHECY Trial: Circulating Tumor Cell as a Biomarker in mCRPC - Andrew Armstrong

Details
(Length of Discussion: 12 min) Charles Ryan and Andrew Armstrong discuss the PROPHECY study, a PCF challenge award, co-funded by Movember. Seeing the future with predictive biomarkers was the foundational vision for this study. For men with castration-resistant prostate cancer undergoing a range of therapies, two AR-V7 tests were prospectively compared to see how well they predicted both progressi...

STAMPEDE Trial Updates in Prostate Cancer - Silke Gillessen

Details
(Length of Discussion: 12 min) Silke Gillessen and Alicia Morgans discuss recent data from the STAMPEDE trial. Local radiotherapy improving survival in metastatic prostate cancer with low disease burden and the subanalysis looking at the effects of abiraterone acetate plus prednisone in both high and low metastatic hormone-sensitive prostate cancer. Silke shares the clinical trial design and data...